# Inhibition of Aldosterone to Reduce Myocardial Diffuse Fibrosis in Patients With Paroxysmal and Persistent Atrial Fibrillation in Preventing Recurrent Episodes of Atrial Fibrillation

Study · id `cardio:ct-nct02764619` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02764619](<https://clinicaltrials.gov/study/NCT02764619>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02764619

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 125 participants.

## Technical summary

Registry record NCT02764619. Randomized; quadruple masking; primary purpose treatment. Start 2013-12 (registry gives no type); primary completion 2017-02 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 125 participants (enrolled count; ClinicalTrials.gov record NCT02764619, source copy `cardio:ctgov-nct02764619-2016-05-17`, retrieved 2026-10-26)
- Start date: 2013-12 (registry gives no type) (ClinicalTrials.gov record NCT02764619, source copy `cardio:ctgov-nct02764619-2016-05-17`, retrieved 2026-10-26)
- Primary completion: 2017-02 (anticipated) (ClinicalTrials.gov record NCT02764619, source copy `cardio:ctgov-nct02764619-2016-05-17`, retrieved 2026-10-26)
- Completion: 2017-04 (anticipated) (ClinicalTrials.gov record NCT02764619, source copy `cardio:ctgov-nct02764619-2016-05-17`, retrieved 2026-10-26)
- Countries: Denmark (ClinicalTrials.gov record NCT02764619, source copy `cardio:ctgov-nct02764619-2016-05-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02764619-2016-05-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: Inhibition of Aldosterone to Reduce Myocardial Diffuse Fibrosis in Patients With Paroxysmal and Persistent Atrial Fibrillation in Preventing Recurrent Episodes of Atrial Fibrillation
- Acronym: INSPIRE-AF
- Condition: Atrial Fibrillation
- Intervention (Drug): Spironolactone
- Intervention (Drug): Placebo
- Lead sponsor: Svendborg Hospital
- Lead sponsor class: OTHER
- Collaborator: Region of Southern Denmark
- Collaborator class: OTHER
- Collaborator: Takeda
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as a collaborator: Region of Southern Denmark (`cardio:org-region-of-southern-denmark`)
- Registry lists this organization as a collaborator: Takeda (`cardio:org-takeda`)

## Provenance

Content hash: 7cfb5348aeb620471d8a1c3077e1482bcd3e6a84174b3115c7cdba94a88d9b47
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
